Biopsy devices market seen reaching $3.65 billion by 2035

Market Research Future projects the global biopsy devices market will grow from $2.50 billion in 2026 to $3.65 billion by 2035, driven by cancer screening mandates, AI-guided procedures and more outpatient biopsies. The outlook points to stronger demand in breast and lung applications, with North America leading and Asia-Pacific growing fastest.

Why it matters: - The biopsy devices market is tied directly to cancer diagnosis, so higher screening rates and more confirmed cases translate into more device use. - Market Research Future forecasts the global market will rise from $2.50 billion in 2026 to $3.65 billion by 2035, up from a $2.40 billion base in 2025. - The projected 4.30% CAGR reflects policy-driven demand, not discretionary spending. - Request a free sample

What happened: - Market Research Future released a new outlook for the global biopsy devices market covering 2026-2035. - The report links growth to government-funded screening mandates, AI-integrated image-guidance platforms and ambulatory surgical center expansion. - The report says the market is shifting from hospital-heavy workflows toward more outpatient and precision-guided procedures.

The details: - The International Agency for Research on Cancer projects 35 million new cancer cases a year by 2050, up 77% from 2022. - Breast, lung and colorectal cancers account for about 38% of those cases. - More than 90 countries have national cancer-control strategies requiring pathology-confirmed staging before treatment. - Australia’s 2025 bulk-billed low-dose CT lung-screening program is expected to add about 180,000 CT scans a year, with a projected 5% to 8% biopsy conversion rate. - The EU’s Beating Cancer Plan is allocating EUR 4 billion across member states. - The U.S. Preventive Services Task Force expanded lung-screening eligibility in 2021 to adults with a 20-pack-year history starting at age 50, widening the addressable population by roughly 6.5 million people. - National cancer registries in India and Brazil are capturing higher detection rates as screening programs mature. - AI-integrated biopsy systems are cutting procedural time by an estimated 30% to 40% and lifting specimen adequacy above 95%. - Real-time specimen verification reduces non-diagnostic rates from 8% to 12% to under 3%. - Device makers are embedding algorithms into console software, lifting average selling prices by 15% to 22% per unit. - Medtronic launched an AI-fused stereotactic platform in 2024. - Hologic acquired an automated specimen-verification startup. - Regulatory agencies in the U.S. and EU have streamlined 510(k) and CE-MDR pathways for single-use biopsy instruments. - AI-guided platforms require 15 to 25 supervised cases for operator proficiency certification. - Simulation-based training can compress the learning curve to under one week. - By 2035, autonomous biopsy navigation is projected to reduce operator-dependent variability by more than 50%. - By 2030, machine-learning features for real-time lesion segmentation and autonomous needle-path planning are expected to be standard on mid-range and premium biopsy consoles. - There were about 6,100 U.S. ambulatory surgical centers in 2024, with more than 200 added each year on average. - Medicare and commercial payors now reimburse outpatient breast and thyroid biopsies at rates similar to hospital outpatient departments. - Medicare’s 2024 ASC-approved CPT code expansion is a near-term catalyst for outpatient migration. - Single-use devices eliminate reprocessing labor and sterilization costs, averaging USD 12 to 18 per cycle. - In facilities performing more than 500 annual procedures, single-use total cost of ownership is roughly equivalent to reusable platforms within three years. - China allocated ¥120 billion to county-level hospital diagnostic upgrades in its 14th Five-Year Plan. - India’s Ayushman Bharat scheme funded 182,879 new health-and-wellness centers in early 2026, with 8,000 more targeted through 2028.

Between the lines: - The report’s core thesis is that biopsy demand is becoming more predictable because screening programs, reimbursement policy and diagnostic guidelines are all pushing in the same direction. - AI guidance is not just a clinical upgrade. It is also a pricing lever, since bundled hardware-software systems support higher margins and create switching costs. - The shift to outpatient settings favors single-use kits and faster turnover, which helps suppliers selling consumables rather than reusable capital equipment. - North America’s lead reflects reimbursement and adoption speed, while Asia-Pacific’s growth reflects public infrastructure spending and health-center expansion. - The market remains moderately concentrated, with the top five companies holding an estimated 48% to 55% combined share.

What's next: - The report expects precision AI-guided biopsy theranostics to become a core operating model by 2030. - By 2030, about 40% of newly diagnosed lung cancer patients are expected to undergo low-dose CT screening followed by matched AI-navigated biopsy. - Machine-learning models that combine genomic, proteomic and imaging biomarkers are expected to guide needle and technique selection. - Start-ups have raised more than USD 800 million in venture funding for oncology decision-support tools since 2023. - Read the detailed report

The bottom line: - Biopsy devices are moving from a procedural niche to a screening-linked, AI-enabled and outpatient-driven market, with policy support likely to keep volumes rising through 2035.